Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 10, 2022
Share
Ever Supreme Bio Technology Co., Ltd reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 152.63 million compared to TWD 91.05 million a year ago. Net income was TWD 41.56 million compared to TWD 67.69 million a year ago. Basic earnings per share from continuing operations was TWD 0.5547 compared to TWD 0.9094 a year ago. Diluted earnings per share from continuing operations was TWD 0.5547 compared to TWD 0.9003 a year ago.
For the six months, sales was TWD 276.12 million compared to TWD 140.04 million a year ago. Net income was TWD 32.3 million compared to TWD 54.25 million a year ago. Basic earnings per share from continuing operations was TWD 0.4274 compared to TWD 0.7275 a year ago. Diluted earnings per share from continuing operations was TWD 0.4274 compared to TWD 0.7184 a year ago.
Ever Supreme Bio Technology Co., Ltd. is a Taiwan-based company mainly engaged in the research, design, development, manufacture and sales of stem cell products and immune cell products. The Company has three main products. ADCV01 is an autologous dendritic cell tumor vaccine product, which is currently in the phaseII of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product and a new drug for the treatment of myocardial infarction, which is approved by the United States Food and Drug Administration (FDA) clinical phaseI and is currently applying for the phaseI of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product, which is used to treat acute ischemic stroke and is currently in the United States FDA for clinical phase I. The Company plans to develop new products and services including mesenchymal stem cells for the treatment of multiple sclerosis.
EVER SUPREME BIO TECHNOLOGY CO., LTD 
